Clinical trial
A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Paclitaxel in the Treatment of Subjects With Solid Tumors
NCT00891605 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Paclitaxel in the Treatment of Subjects With Solid Tumors
- Lead sponsor
- AbbVie
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2009
- Completion date
- July 31, 2012
- Enrollment
- 19 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumors